Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta-2-microglobulin siRNA
- Development stage
- Preclinical
- Lead developer
- University of Nebraska Medical Center
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Beta-2-microglobulin (B2M) siRNA is a small interfering RNA designed to silence the expression of the B2M gene. B2M is the light chain component of the Human Leukocyte Antigen (HLA) class I molecule, which is essential for the cell-surface expression of HLA class I and antigen presentation to cytotoxic T cells. In the context of oncology research, particularly in pancreatic cancer, B2M siRNA is used to investigate the role of HLA class I components in tumor cell proliferation and migration. Studies have shown that down-regulation of B2M can influence the growth and invasive properties of cancer cells, suggesting that HLA class I molecules may provide a survival or progression advantage to certain tumors beyond their traditional immune functions. While primarily used as a research tool, B2M modulation is also a key strategy in the development of allogeneic cell therapies to reduce immunogenicity.
- Other names
- B2M siRNAB-2M siRNAB 2M siRNAβ2m siRNA
02
Targets
B2M (Beta-2-microglobulin)Innate immune RNA sensors
Beyond the preview
Go deeper on beta-2-microglobulin siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beta-2-microglobulin siRNA.